IRWD's Linzess wins FDA nod for expanded pediatric constipation use
- Posted on May 28, 2026
- By Bing News
- 0 Views
- 1 min read
IRWD's Linzess wins FDA nod for expanded pediatric constipation use
Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess (linaclotide), for the treatment of functional constipation (FC) in pediatric patients aged two years and older. The therapy was approved for FC in children and adolescents aged six to 17 years in 2023. Linzess is the only FDA-approved daily treatment for pediatric FC. Although the FDA decision was expected on May 24, 2026, the...
